APG Asset Management N.V. acquired a new stake in BIOVERATIV INC (NASDAQ:BIVV) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 53,400 shares of the biotechnology company’s stock, valued at approximately $3,048,000.

A number of other hedge funds have also recently made changes to their positions in the business. Mutual of America Capital Management LLC purchased a new position in BIOVERATIV INC in the 3rd quarter valued at $5,062,000. State Treasurer State of Michigan purchased a new position in shares of BIOVERATIV INC during the 3rd quarter worth $2,323,000. Farmers & Merchants Investments Inc. purchased a new position in shares of BIOVERATIV INC during the 3rd quarter worth $1,837,000. Rockefeller Financial Services Inc. purchased a new position in shares of BIOVERATIV INC during the 3rd quarter worth $1,480,000. Finally, Meeder Asset Management Inc. purchased a new position in shares of BIOVERATIV INC during the 3rd quarter worth $877,000. Institutional investors own 93.07% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “APG Asset Management N.V. Invests $3.05 Million in BIOVERATIV INC (BIVV) Stock” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.watchlistnews.com/apg-asset-management-n-v-invests-3-05-million-in-bioverativ-inc-bivv-stock/1685064.html.

In other BIOVERATIV INC news, Director Brian S. Posner acquired 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 9th. The stock was purchased at an average cost of $59.19 per share, with a total value of $59,190.00. Following the transaction, the director now owns 6,693 shares of the company’s stock, valued at $396,158.67. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of BIOVERATIV INC (BIVV) opened at $52.85 on Tuesday. BIOVERATIV INC has a 52-week low of $40.00 and a 52-week high of $64.41.

BIOVERATIV INC (NASDAQ:BIVV) last issued its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.25. The firm had revenue of $291.60 million during the quarter, compared to the consensus estimate of $285.45 million. BIOVERATIV INC had a return on equity of 69.03% and a net margin of 40.44%. The firm’s revenue was up 27.2% compared to the same quarter last year. equities analysts anticipate that BIOVERATIV INC will post 2.45 EPS for the current year.

Several research firms have recently commented on BIVV. Zacks Investment Research upgraded BIOVERATIV INC from a “hold” rating to a “strong-buy” rating and set a $73.00 price target on the stock in a report on Tuesday, July 25th. Cowen and Company reiterated a “buy” rating and set a $80.00 price target on shares of BIOVERATIV INC in a report on Friday, August 4th. Piper Jaffray Companies reiterated an “overweight” rating and set a $71.00 price target on shares of BIOVERATIV INC in a report on Monday, October 23rd. Jefferies Group LLC reiterated a “buy” rating and set a $70.00 price target (up previously from $67.00) on shares of BIOVERATIV INC in a report on Wednesday, August 9th. Finally, Morgan Stanley reiterated an “underweight” rating and set a $47.00 price target (up previously from $45.00) on shares of BIOVERATIV INC in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $61.73.

BIOVERATIV INC Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BIOVERATIV INC (NASDAQ:BIVV).

Institutional Ownership by Quarter for BIOVERATIV INC (NASDAQ:BIVV)

Receive News & Ratings for BIOVERATIV INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOVERATIV INC and related companies with Analyst Ratings Network's FREE daily email newsletter.